Timber pharmaceuticals receives orphan drug designation from u.s. fda for tmb-003 for the treatment of systemic sclerosis

Timber expects to submit investigational new drug (ind) application to the fda in 2022
TMBR Ratings Summary
TMBR Quant Ranking